Groupama Asset Managment Has $728,000 Stock Holdings in ResMed Inc. $RMD

Groupama Asset Managment decreased its position in ResMed Inc. (NYSE:RMD) by 51.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,658 shares of the medical equipment provider’s stock after selling 2,834 shares during the period. Groupama Asset Managment’s holdings in ResMed were worth $728,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. lifted its position in ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 86 shares during the period. Imprint Wealth LLC bought a new position in shares of ResMed in the 3rd quarter valued at about $26,000. WFA of San Diego LLC acquired a new stake in shares of ResMed during the 2nd quarter worth approximately $26,000. Sunbelt Securities Inc. acquired a new stake in shares of ResMed during the 3rd quarter worth approximately $31,000. Finally, Westside Investment Management Inc. raised its stake in shares of ResMed by 100.0% during the third quarter. Westside Investment Management Inc. now owns 132 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 66 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RMD. Robert W. Baird set a $281.00 price objective on shares of ResMed in a report on Friday, January 30th. Royal Bank Of Canada lifted their target price on shares of ResMed from $311.00 to $314.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. UBS Group reiterated a “buy” rating and set a $345.00 target price on shares of ResMed in a research report on Friday, December 12th. Weiss Ratings downgraded ResMed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Finally, KeyCorp reaffirmed an “overweight” rating and set a $302.00 price objective on shares of ResMed in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, ResMed has an average rating of “Moderate Buy” and a consensus target price of $299.27.

Insider Buying and Selling

In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $260.22, for a total transaction of $520,440.00. Following the completion of the transaction, the director directly owned 62,773 shares in the company, valued at approximately $16,334,790.06. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $251.03, for a total value of $1,252,890.73. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company’s stock, valued at $117,035,959.69. The trade was a 1.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 21,073 shares of company stock worth $5,405,198 in the last 90 days. Company insiders own 0.65% of the company’s stock.

ResMed Stock Performance

ResMed stock opened at $226.46 on Friday. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06. The stock has a market cap of $32.99 billion, a PE ratio of 22.40, a P/E/G ratio of 1.51 and a beta of 0.88. ResMed Inc. has a 12-month low of $199.92 and a 12-month high of $293.81. The business’s 50-day moving average price is $253.06 and its two-hundred day moving average price is $256.85.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The firm had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the prior year, the business earned $2.43 earnings per share. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. As a group, analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Investors of record on Thursday, February 12th were paid a $0.60 dividend. The ex-dividend date of this dividend was Thursday, February 12th. This represents a $2.40 annualized dividend and a yield of 1.1%. ResMed’s dividend payout ratio is presently 23.74%.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.